181 related articles for article (PubMed ID: 38256007)
1. Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.
Kaneda-Nakashima K; Shirakami Y; Kadonaga Y; Watabe T; Ooe K; Yin X; Haba H; Shirasaki K; Kikunaga H; Tsukada K; Toyoshima A; Cardinale J; Giesel FL; Fukase K
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256007
[TBL] [Abstract][Full Text] [Related]
2. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
[TBL] [Abstract][Full Text] [Related]
3. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
4. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
6. Targeted alpha therapy of mCRPC: Dosimetry estimate of
Kratochwil C; Schmidt K; Afshar-Oromieh A; Bruchertseifer F; Rathke H; Morgenstern A; Haberkorn U; Giesel FL
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):31-37. PubMed ID: 28891033
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8.
Nonnekens J; Chatalic KL; Molkenboer-Kuenen JD; Beerens CE; Bruchertseifer F; Morgenstern A; Veldhoven-Zweistra J; Schottelius M; Wester HJ; van Gent DC; van Weerden WM; Boerman OC; de Jong M; Heskamp S
Cancer Biother Radiopharm; 2017 Mar; 32(2):67-73. PubMed ID: 28301262
[TBL] [Abstract][Full Text] [Related]
9. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
[TBL] [Abstract][Full Text] [Related]
10. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the tolerability and safety of [
Ling SW; van der Veldt AAM; Konijnenberg M; Segbers M; Hooijman E; Bruchertseifer F; Morgenstern A; de Blois E; Brabander T
BMC Cancer; 2024 Jan; 24(1):146. PubMed ID: 38287346
[TBL] [Abstract][Full Text] [Related]
12. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
13. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with
van der Doelen MJ; Mehra N; van Oort IM; Looijen-Salamon MG; Janssen MJR; Custers JAE; Slootbeek PHJ; Kroeze LI; Bruchertseifer F; Morgenstern A; Haberkorn U; Kratochwil C; Nagarajah J; Gerritsen WR
Urol Oncol; 2021 Oct; 39(10):729.e7-729.e16. PubMed ID: 33353867
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of
Banerjee SR; Lisok A; Minn I; Josefsson A; Kumar V; Brummet M; Boinapally S; Brayton C; Mease RC; Sgouros G; Hobbs RF; Pomper MG
J Nucl Med; 2021 Jul; 62(7):980-988. PubMed ID: 33246975
[TBL] [Abstract][Full Text] [Related]
16. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [
Stenberg VY; Juzeniene A; Chen Q; Yang X; Bruland ØS; Larsen RH
J Labelled Comp Radiopharm; 2020 Mar; 63(3):129-143. PubMed ID: 31919866
[TBL] [Abstract][Full Text] [Related]
17. Albumin-Binding and Conventional PSMA Ligands in Combination with
Tschan VJ; Busslinger SD; Bernhardt P; Grundler PV; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C
J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604
[TBL] [Abstract][Full Text] [Related]
18. In situ Generated
Stenberg VY; Juzeniene A; Bruland ØS; Larsen RH
Curr Radiopharm; 2020; 13(2):130-141. PubMed ID: 32389119
[TBL] [Abstract][Full Text] [Related]
19. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
20.
Ballal S; Yadav MP; Sahoo RK; Tripathi M; Dwivedi SN; Bal C
Prostate; 2021 Jun; 81(9):580-591. PubMed ID: 33905559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
